FOLD
Price
$9.78
Change
+$0.05 (+0.51%)
Updated
Dec 3 closing price
Capitalization
3.02B
77 days until earnings call
Intraday BUY SELL Signals
MDXG
Price
$6.96
Change
+$0.23 (+3.42%)
Updated
Dec 3, 04:59 PM (EDT)
Capitalization
987.84M
90 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

FOLD vs MDXG

Header iconFOLD vs MDXG Comparison
Open Charts FOLD vs MDXGBanner chart's image
Amicus Therapeutics
Price$9.78
Change+$0.05 (+0.51%)
Volume$2.92M
Capitalization3.02B
MiMedx Group
Price$6.96
Change+$0.23 (+3.42%)
Volume$7.45K
Capitalization987.84M
FOLD vs MDXG Comparison Chart in %
View a ticker or compare two or three
VS
FOLD vs. MDXG commentary
Dec 04, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is FOLD is a StrongBuy and MDXG is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Dec 04, 2025
Stock price -- (FOLD: $9.73 vs. MDXG: $6.72)
Brand notoriety: FOLD and MDXG are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: FOLD: 33% vs. MDXG: 20%
Market capitalization -- FOLD: $3.03B vs. MDXG: $987.84M
FOLD [@Biotechnology] is valued at $3.03B. MDXG’s [@Biotechnology] market capitalization is $987.84M. The market cap for tickers in the [@Biotechnology] industry ranges from $107.98B to $0. The average market capitalization across the [@Biotechnology] industry is $2.19B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

FOLD’s FA Score shows that 0 FA rating(s) are green whileMDXG’s FA Score has 1 green FA rating(s).

  • FOLD’s FA Score: 0 green, 5 red.
  • MDXG’s FA Score: 1 green, 4 red.
According to our system of comparison, MDXG is a better buy in the long-term than FOLD.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

FOLD’s TA Score shows that 2 TA indicator(s) are bullish while MDXG’s TA Score has 4 bullish TA indicator(s).

  • FOLD’s TA Score: 2 bullish, 4 bearish.
  • MDXG’s TA Score: 4 bullish, 6 bearish.
According to our system of comparison, both FOLD and MDXG are a bad buy in the short-term.

Price Growth

FOLD (@Biotechnology) experienced а -1.42% price change this week, while MDXG (@Biotechnology) price change was -3.38% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +0.32%. For the same industry, the average monthly price growth was +1.23%, and the average quarterly price growth was +54.93%.

Reported Earning Dates

FOLD is expected to report earnings on Feb 19, 2026.

MDXG is expected to report earnings on Mar 04, 2026.

Industries' Descriptions

@Biotechnology (+0.32% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
FOLD($3.02B) has a higher market cap than MDXG($988M). FOLD YTD gains are higher at: 3.291 vs. MDXG (-30.198). MDXG has higher annual earnings (EBITDA): 52.7M vs. FOLD (33.1M). FOLD has more cash in the bank: 231M vs. MDXG (119M). MDXG has less debt than FOLD: MDXG (18.5M) vs FOLD (443M). FOLD has higher revenues than MDXG: FOLD (571M) vs MDXG (364M).
FOLDMDXGFOLD / MDXG
Capitalization3.02B988M305%
EBITDA33.1M52.7M63%
Gain YTD3.291-30.198-11%
P/E RatioN/A24.70-
Revenue571M364M157%
Total Cash231M119M194%
Total Debt443M18.5M2,395%
FUNDAMENTALS RATINGS
FOLD vs MDXG: Fundamental Ratings
FOLD
MDXG
OUTLOOK RATING
1..100
5050
VALUATION
overvalued / fair valued / undervalued
1..100
56
Fair valued
73
Overvalued
PROFIT vs RISK RATING
1..100
10093
SMR RATING
1..100
9551
PRICE GROWTH RATING
1..100
4061
P/E GROWTH RATING
1..100
10011
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

FOLD's Valuation (56) in the Biotechnology industry is in the same range as MDXG (73). This means that FOLD’s stock grew similarly to MDXG’s over the last 12 months.

MDXG's Profit vs Risk Rating (93) in the Biotechnology industry is in the same range as FOLD (100). This means that MDXG’s stock grew similarly to FOLD’s over the last 12 months.

MDXG's SMR Rating (51) in the Biotechnology industry is somewhat better than the same rating for FOLD (95). This means that MDXG’s stock grew somewhat faster than FOLD’s over the last 12 months.

FOLD's Price Growth Rating (40) in the Biotechnology industry is in the same range as MDXG (61). This means that FOLD’s stock grew similarly to MDXG’s over the last 12 months.

MDXG's P/E Growth Rating (11) in the Biotechnology industry is significantly better than the same rating for FOLD (100). This means that MDXG’s stock grew significantly faster than FOLD’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
FOLDMDXG
RSI
ODDS (%)
Bearish Trend 6 days ago
75%
Bearish Trend 6 days ago
88%
Stochastic
ODDS (%)
Bearish Trend 6 days ago
81%
Bullish Trend 6 days ago
79%
Momentum
ODDS (%)
N/A
Bearish Trend 6 days ago
82%
MACD
ODDS (%)
N/A
Bearish Trend 6 days ago
84%
TrendWeek
ODDS (%)
Bullish Trend 6 days ago
71%
Bullish Trend 6 days ago
75%
TrendMonth
ODDS (%)
Bullish Trend 6 days ago
74%
Bullish Trend 6 days ago
72%
Advances
ODDS (%)
Bullish Trend 10 days ago
69%
Bullish Trend 9 days ago
77%
Declines
ODDS (%)
Bearish Trend 27 days ago
75%
Bearish Trend 15 days ago
79%
BollingerBands
ODDS (%)
Bearish Trend 6 days ago
86%
Bullish Trend 6 days ago
74%
Aroon
ODDS (%)
Bullish Trend 6 days ago
76%
Bullish Trend 6 days ago
68%
View a ticker or compare two or three
Interact to see
Advertisement
FOLD
Daily Signal:
Gain/Loss:
MDXG
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
EQNRX23.90N/A
N/A
MFS Equity Income R1
MXYKX5.30N/A
N/A
Empower T. Rowe Price Mid Cp Gr Instl
RYLGX111.32N/A
N/A
Rydex S&P 500 Pure Growth A
FCNSX19.32N/A
N/A
Fidelity Series Canada
ILGGX24.92N/A
N/A
Columbia Integrated Large Cap Gr Instl

FOLD and

Correlation & Price change

A.I.dvisor indicates that over the last year, FOLD has been loosely correlated with RARE. These tickers have moved in lockstep 45% of the time. This A.I.-generated data suggests there is some statistical probability that if FOLD jumps, then RARE could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To FOLD
1D Price
Change %
FOLD100%
-0.71%
RARE - FOLD
45%
Loosely correlated
+0.28%
XNCR - FOLD
45%
Loosely correlated
-3.15%
BMRN - FOLD
44%
Loosely correlated
-2.07%
KURA - FOLD
44%
Loosely correlated
-2.53%
CLDX - FOLD
44%
Loosely correlated
+2.85%
More

MDXG and

Correlation & Price change

A.I.dvisor indicates that over the last year, MDXG has been loosely correlated with AXON. These tickers have moved in lockstep 47% of the time. This A.I.-generated data suggests there is some statistical probability that if MDXG jumps, then AXON could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To MDXG
1D Price
Change %
MDXG100%
+0.67%
AXON - MDXG
47%
Loosely correlated
+0.91%
VCYT - MDXG
42%
Loosely correlated
-0.43%
FOLD - MDXG
41%
Loosely correlated
-0.71%
ARRY - MDXG
39%
Loosely correlated
-0.13%
RAPT - MDXG
38%
Loosely correlated
+2.76%
More